Pipobroman
![]() | |
| Systematic (IUPAC) name | |
|---|---|
|
3-bromo-1-[4-(3-bromopropanoyl) piperazin-1-yl]-propan-1-one | |
| Clinical data | |
| Trade names | Vercite, Vercyte |
| AHFS/Drugs.com | International Drug Names |
| Identifiers | |
| CAS Number |
54-91-1 |
| ATC code | L01AX02 (WHO) |
| PubChem | CID 4842 |
| IUPHAR/BPS | 7271 |
| DrugBank |
DB00236 |
| ChemSpider |
4676 |
| UNII |
6Q99RDT97R |
| KEGG |
D00467 |
| ChEMBL |
CHEMBL1585 |
| Chemical data | |
| Formula | C10H16Br2N2O2 |
| Molar mass | 356.054 g/mol |
| |
| |
| (verify) | |
Pipobroman (trade names Vercite, Vercyte) is an anti-cancer drug that probably acts as an alkylating agent.[1] It is marketed by Abbott Laboratories.[2]
References
- ↑ Passamonti, F.; Lazzarino, M. (2003). "Treatment of Polycythemia Vera and Essential Thrombocythemia: The Role of Pipobroman". Leukemia & Lymphoma 44 (9): 1483–1488. doi:10.3109/10428190309178768. PMID 14565648.
- ↑ Drugs.com: Pipobroman
| ||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
